Sort   by:  
 Page size 
UnknownMetronomic Chemotherapy: Anti-Tumor Pathways and Combination with Immune Checkpoint Inhibitors.
Not available
S-EPMC10177461 | biostudies-literature
UnknownNew Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma.
Not available
S-EPMC6721310 | biostudies-literature
UnknownThe Molecular and Microenvironmental Landscape of Glioblastomas: Implications for the Novel Treatment Choices.
Not available
S-EPMC7724040 | biostudies-literature
UnknownNew insights into human papillomavirus-associated head and neck squamous cell carcinoma.
Not available
S-EPMC3665382 | biostudies-literature
UnknownBaseline systemic inflammatory indices predict late radiation-induced fibrosis and toxicity in patients with early breast cancer.
Not available
S-EPMC12813060 | biostudies-literature
UnknownLoss of Spry1 reduces growth of BRAFV600-mutant cutaneous melanoma and improves response to targeted therapy.
Not available
S-EPMC7244546 | biostudies-literature
ProteomicsSpry1 as a potential new hypoxia modulator in cutaneous melanoma
Introduction. At present, the precise role of Spry proteins in tumor progression is still debated. Our previous study showed that Spry1 knockdown (Spry1KO) in BRAFV600-mutant cutaneous melanoma (CM) promoted cell cycle arrest and apoptosis, repressed cell proliferation in vitro, and reduced tumor gr...
ORGANISM(S): Homo sapiens (Human) 
2025-05-06 | PXD038916 | Pride
Cutaneous melanoma Hypoxia Braf Ip-ms Spry1 
UnknownSuppression of Spry1 reduces HIF1α-dependent glycolysis and impairs angiogenesis in BRAF-mutant cutaneous melanoma.
Not available
S-EPMC11827140 | biostudies-literature
UnknownLINE-1 hypomethylation is associated with poor outcomes in locoregionally advanced oropharyngeal cancer.
Not available
S-EPMC9743592 | biostudies-literature
Sort   by:  
 Page size